Amphastar Pharmaceuticals EBITDA 2012-2024 | AMPH
Amphastar Pharmaceuticals ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Amphastar Pharmaceuticals Annual EBITDA
(Millions of US $) |
| 2023 |
$246 |
| 2022 |
$133 |
| 2021 |
$93 |
| 2020 |
$32 |
| 2019 |
$18 |
| 2018 |
$8 |
| 2017 |
$15 |
| 2016 |
$30 |
| 2015 |
$6 |
| 2014 |
$-4 |
| 2013 |
$31 |
| 2012 |
$37 |
| 2011 |
$-22 |
| 2009 |
$35 |
Amphastar Pharmaceuticals Quarterly EBITDA
(Millions of US $) |
| 2024-06-30 |
$71 |
| 2024-03-31 |
$63 |
| 2023-12-31 |
$70 |
| 2023-09-30 |
$91 |
| 2023-06-30 |
$46 |
| 2023-03-31 |
$40 |
| 2022-12-31 |
$44 |
| 2022-09-30 |
$30 |
| 2022-06-30 |
$31 |
| 2022-03-31 |
$28 |
| 2021-12-31 |
$30 |
| 2021-09-30 |
$30 |
| 2021-06-30 |
$17 |
| 2021-03-31 |
$16 |
| 2020-12-31 |
$9 |
| 2020-09-30 |
$9 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$12 |
| 2019-12-31 |
$5 |
| 2019-09-30 |
$7 |
| 2019-06-30 |
$5 |
| 2019-03-31 |
$1 |
| 2018-12-31 |
$6 |
| 2018-09-30 |
$7 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$-6 |
| 2017-12-31 |
$2 |
| 2017-09-30 |
$1 |
| 2017-06-30 |
$6 |
| 2017-03-31 |
$5 |
| 2016-12-31 |
$-1 |
| 2016-09-30 |
$10 |
| 2016-06-30 |
$14 |
| 2016-03-31 |
$8 |
| 2015-12-31 |
$18 |
| 2015-09-30 |
$-0 |
| 2015-06-30 |
$-7 |
| 2015-03-31 |
$-4 |
| 2014-12-31 |
$-3 |
| 2014-09-30 |
$-4 |
| 2014-06-30 |
$2 |
| 2014-03-31 |
$1 |
| 2013-12-31 |
$6 |
| 2013-09-30 |
$3 |
| 2013-06-30 |
$15 |
| 2013-03-31 |
$5 |
| 2012-12-31 |
$52 |
| 2012-09-30 |
$57 |
| 2012-06-30 |
$49 |
| 2012-03-31 |
$46 |
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.469B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
